product summary
Loading...
company name :
R&D Systems
product type :
ELISA/assay
product name :
Human sgp130 DuoSet ELISA
catalog :
DY228
quantity :
1 Kit (for 15 Plates)
price :
850 USD
more info or order :
citations: 10
Reference |
---|
Rabe B, Chalaris A, May U, Waetzig G, Seegert D, Williams A, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood. 2008;111:1021-8 pubmed
|
image
image 1 :

Human gp130 ELISA Standard Curve
product information
master code :
DY228
SKU :
DY228
product name :
Human sgp130 DuoSet ELISA
unit size :
1 Kit (for 15 Plates)
description :
The Human sgp130 DuoSet ELISA from R&D Systems is a Solid Phase Sandwich ELISA that quantifies human gp130/CD130.
target :
gp130
category :
ELISAs
species :
Human
gene symbol :
IL6ST
kit type :
Solid Phase Sandwich ELISA
elisaRange :
156.00 - 10000 pg/mL
top caption :
Human gp130 ELISA Standard Curve
applications :
ELISA
USD :
850 USD
alt names :
CD130, CD130 antigen, CDw130, DKFZp564F053, gp130, gp130 of the rheumatoid arthritis antigenic peptide-bearing soluble form, IL-6 receptor subunit beta, IL-6R subunit beta, IL-6RB, IL-6R-beta, IL6ST, interleukin 6 signal transducer (gp130, oncostatin M receptor), interleukin receptor beta chain, interleukin-6 receptor subunit beta, Interleukin-6 signal transducer, Membrane glycoprotein 130, membrane glycoprotein gp130, Oncostatin-M receptor subunit alpha
storage :
Store the unopened product at 2 - 8 ░C. Do not use past expiration date.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
related products
browse more products
questions and comments